Vectalys
Provider of lentiviral-based delivery technologies and CDMO services for research, pre-clinical and clinical gene & cell therapy. Offers integrative lentiviral vector design and production, a non-integrative RNA delivery particle format for transient expression, purification and titration methods to maximize functional particle quality, and scale-up/GMP manufacturing support.
Industries
Nr. of Employees
small (1-50)
Vectalys
Canal Biotech II, 3 rue des satellites, 31400 Toulouse, France
Products
Ready-to-use integrative lentiviral particles (reporters and gene editing)
Pre-made integrative lentiviral particle products including fluorescent reporters, bioluminescent reporters, and vectors configured for gene editing or specific promoters for rapid testing and assays.
Ready-to-use non-integrative RNA lentiviral particles (reporters, Cre, Cas9)
Pre-made non-integrative RNA-packaging particles for transient expression including luciferase reporter, recombinase and nuclease mRNA formats for gene editing tests and in vivo/transient applications.
Plasmid packaging mixes for non-integrative RNA particle production
Plasmid kits and packaging mixes enabling in-lab production of non-integrative RNA-packaging particles for academic research use.
Ready-to-use integrative lentiviral particles (reporters and gene editing)
Pre-made integrative lentiviral particle products including fluorescent reporters, bioluminescent reporters, and vectors configured for gene editing or specific promoters for rapid testing and assays.
Ready-to-use non-integrative RNA lentiviral particles (reporters, Cre, Cas9)
Pre-made non-integrative RNA-packaging particles for transient expression including luciferase reporter, recombinase and nuclease mRNA formats for gene editing tests and in vivo/transient applications.
Plasmid packaging mixes for non-integrative RNA particle production
Plasmid kits and packaging mixes enabling in-lab production of non-integrative RNA-packaging particles for academic research use.
Services
Design and manufacture of custom integrative lentiviral vectors with selectable purification/quality tiers for applications from cell line generation to in vivo experiments; scale-up and GMP transfer available.
Production of highly purified non-integrative RNA-packaging particles for transient expression and multiplex RNA delivery (e.g., sgRNA, Cas9 mRNA, antigens), with premium purification for sensitive cell types.
Production of larger batch volumes with consistent titer and purity for pre-clinical studies and animal models, enabling use of the same vector composition from research to pre-clinical stages.
Stepwise qualification plan and GMP-grade production capabilities (including partnership-operated GMP facilities) for clinical-grade lentiviral and RNA particle manufacturing and associated quality control.
Advisory and hands-on support for vector construction choices, purification level selection, titration strategy and downstream experimental design to maximize transduction efficiency and preserve cell phenotype.
Design and manufacture of custom integrative lentiviral vectors with selectable purification/quality tiers for applications from cell line generation to in vivo experiments; scale-up and GMP transfer available.
Production of highly purified non-integrative RNA-packaging particles for transient expression and multiplex RNA delivery (e.g., sgRNA, Cas9 mRNA, antigens), with premium purification for sensitive cell types.
Production of larger batch volumes with consistent titer and purity for pre-clinical studies and animal models, enabling use of the same vector composition from research to pre-clinical stages.
Stepwise qualification plan and GMP-grade production capabilities (including partnership-operated GMP facilities) for clinical-grade lentiviral and RNA particle manufacturing and associated quality control.
Advisory and hands-on support for vector construction choices, purification level selection, titration strategy and downstream experimental design to maximize transduction efficiency and preserve cell phenotype.
Expertise Areas
- Lentiviral vector manufacturing (integrative and non-integrative)
- Transient RNA delivery for gene editing
- Cell and gene therapy CDMO services (scale-up and GMP transition)
- Immunotherapy and CAR‑T/NK cell transduction
Key Technologies
- Integrative lentiviral vectors
- Non-integrative RNA-packaging lentiviral particles (bacteriophage coat-based)
- CRISPR-Cas9 RNA delivery
- VSV-G pseudotyping
News & Updates
Participation announcement for the ASGCT virtual meeting (May 11-14, 2021 EST).
Participation announcement for the Cell & Gene Therapy Bioprocessing & Commercialization virtual meeting (October 19-22, 2020 EST).
Participation announcement for the 27th ESGCT Annual Meeting (October 22-25, 2019).
Article describing use of non-integrative RNA particles to deliver Cre recombinase in vivo for excision and inversion events in floxed mouse models.
Review-style article discussing CRISPR/Cas9 off-target considerations and DNA repair implications.
Reported production experience of over 6,000 lentiviral vector batches since company founding.
Participation announcement for the ASGCT virtual meeting (May 11-14, 2021 EST).
Participation announcement for the Cell & Gene Therapy Bioprocessing & Commercialization virtual meeting (October 19-22, 2020 EST).
Participation announcement for the 27th ESGCT Annual Meeting (October 22-25, 2019).
Article describing use of non-integrative RNA particles to deliver Cre recombinase in vivo for excision and inversion events in floxed mouse models.
Review-style article discussing CRISPR/Cas9 off-target considerations and DNA repair implications.
Reported production experience of over 6,000 lentiviral vector batches since company founding.